Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...

Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming ...

FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to ...

July 29 - Novo Nordisk (NOVO?B) shares plunged about 20% Tuesday after the Danish drugmaker warned of weaker-than?expected ...

In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...